Hepatitis C is a serious public health problem with more than 170 million chronic carriers worldwide. Although hepatitis C infection can be cured in up to 40% of patients, current treatment is not ideal and is associated with a wide spectrum of side effects and complications. Therefore, emerging evidence suggests that patients can receive tailored therapy based on their viral kinetic changes during treatment. With better knowledge of hepatitis C viral genome and life cycle, compounds so called ''Specifically Targeted Antiviral Therapy for HCV or STAT-C'' are under development. This review will discuss current therapies and recent advances in new therapies for hepatitis C.